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Bruno Dubois8, Frank Jessen9, Laura McWhirter4, Philip Scheltens10,11, Wiesje M. van der Flier10,12, Bruno Vellas13,
Jean-François Démonet14†, Giovanni B. Frisoni1,2†, on behalf of the European Task Force for Brain Health Services
Abstract
Dementia has a devastating impact on the quality of life of patients and families and comes with a huge cost to
society. Dementia prevention is considered a public health priority by the World Health Organization. Delaying the
onset of dementia by treating associated risk factors will bring huge individual and societal benefit. Empirical
evidence suggests that, in higher-income countries, dementia incidence is decreasing as a result of healthier
lifestyles. This observation supports the notion that preventing dementia is possible and that a certain degree of
prevention is already in action. Further reduction of dementia incidence through deliberate prevention plans is
needed to counteract its growing prevalence due to increasing life expectancy.
An increasing number of individuals with normal cognitive performance seek help in the current memory clinics
asking an evaluation of their dementia risk, preventive interventions, or interventions to ameliorate their cognitive
performance. Consistent evidence suggests that some of these individuals are indeed at increased risk of dementia.
This new health demand asks for a shift of target population, from patients with cognitive impairment to worried
but cognitively unimpaired individuals. However, current memory clinics do not have the programs and protocols
in place to deal with this new population.
We envision the development of new services, henceforth called Brain Health Services, devoted to respond to
demands from cognitively unimpaired individuals concerned about their risk of dementia. The missions of Brain
Health Services will be (i) dementia risk profiling, (ii) dementia risk communication, (iii) dementia risk reduction, and
(iv) cognitive enhancement. In this paper, we present the organizational and structural challenges associated with
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the set-up of Brain Health Services.
Keywords: Brain Health Services, Dementia, Aging, Alzheimer’s disease, Prevention, Dementia risk, Risk
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Background
Dementia consists of the cognitive decline from a previ-
ous level of performance to such an extent that it inter-
feres with independence in everyday activities [1]. It
impacts patients and their families and comes with a
huge cost to society. Dementia prevention therefore is
considered a public health priority by the World Health
Organization [2]. Delaying the onset of dementia by
treating underlying diseases will bring huge individual
and societal benefit. Empirical observations in cohorts
born in more recent decades in high-income countries
indicate a reduction of the age-specific incidence of de-
mentia [3–14], suggesting that dementia prevention is
possible and already in action. This is likely the unin-
tended result of greater overall wealth and healthier life-
styles, including better control of cardiovascular risk
factors. Epidemiological evidence allows to estimate that
40% of dementia cases are due to lifestyle and cardiovas-
cular modifiable risk factors [15], while the remaining
cases are largely explained by genetic (e.g., APOE ɛ4),
biological (e.g., amyloid and tau), other unknown risk
factors, and their interactions [16]. However, the bad
news is that dementia prevalence is steadily increasing
worldwide. This is due mainly to population aging in
lower- and middle-income countries and to the in-
creased life span of individuals with dementia in higher-
income countries. Therefore, a further decrease of de-
mentia incidence is needed to counteract the worldwide
trend of increased dementia prevalence. We believe that,
today, evidence is sufficient to set up evidence-based, ef-
fective, personalized, and equitable dementia prevention
plans in persons at risk of dementia.
The current memory clinics have been designed for
the needs of patients with overt cognitive and/or behav-
ioral disorders with the aim of reducing the burden of
progressive decline (tertiary prevention). Nevertheless, a
considerable number of cognitively unimpaired individ-
uals believing that they may be at increased risk of de-
mentia is seeking help in memory clinics, accounting for
20–30% of all patients [17–19]. Increasing and consist-
ent evidence indicates that these have a mildly increased
risk of dementia as compared to the general population
[20]. These individuals present specific concerns, re-
quests, expectations, and hopes different from those of
the cognitively impaired ones, but they are usually dis-
charged with generic recommendations and reassurance,
and no really actionable and meaningful answers.
The development of new and innovative services,
henceforth referred to as Brain Health Services (BHSs),
is needed to provide specific answers to these individ-
uals’ unmet needs. The missions of BHSs consist of (i)
dementia risk profiling, (ii) dementia risk communica-
tion, (iii) dementia risk reduction (primary and second-
ary prevention), and (iv) cognitive enhancement. BHSs
will feature specific knowledge, skills, protocols, and
technology to meet the challenges posed by this new de-
mand. Some pilot experiences are ongoing at the time of
the writing of this article (Q4 2020) in Barcelona, Edin-
burgh, and Paris and have provided ideas and tools for
this article and the others of this series published in this
issue of Alzheimer’s Research & Therapy.
This is the first of six papers, which are part of a larger
initiative of the European Task Force for Brain Health
Services, aiming to draft the protocols of operations in
the BHSs of the future. Here, we describe the
organization, structure, and challenges for implementing
BHSs, while the other papers focus on the four missions
(mentioned above) and on the societal challenges.
BHS organization
In this section, we present how the novel BHS facilities
might be structured at the time of writing of this article
(Q4 2020). In Section 4.1, we envision how BHSs may
look like in the upcoming years based on research ad-
vances and technological innovations.
What is in a name?
Equally tenable denominations could be proposed, em-
phasizing different aspects: i) the biomedical domains
(e.g., brain, dementia, Alzheimer’s disease, memory), (ii)
the clinical mission (e.g., health, prevention), and (iii) the
organizational structure (e.g., clinic, service, unit). The
end result would be labels such as “brain health clinics,”
“dementia prevention services,” etc.
We propose “Brain Health Services” for the following
reasons: (i) the concept of “brain health” is more com-
prehensive than “dementia prevention,” opening to cog-
nitive enhancement which, by definition, aims to
improve cognitive functions rather than preventing de-
mentia, and is one of people’s demands and (ii) the
terms “clinic” and “unit” imply that the services would
be delivered in structures independent of other services,
while we believe that BHSs can be implemented either
within the current memory clinics or as distributed and
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interconnected services (see the “Context for BHS im-
plementation” section). Whatever the label, its semantic
should match the content of the health offer.
Users
The target population of BHSs will consist of older or
middle-aged adults who wish to check their risk of de-
mentia, preserve cognitive functions, or enhance their
cognitive performance. This population includes individ-
uals with subjective cognitive decline (SCD) [21], func-
tional cognitive disorders [19], and the “worried wells.”
Individuals with SCD experience persistent cognitive
decline which is not detected by the standard clinical
and neuropsychological batteries used to detect mild
cognitive impairment and dementia and, although cogni-
tively unimpaired, have an increased risk of dementia as
compared to the general population (incidence of 20.1/
1000 person-year vs 14.2/1000 person-year [20]). Func-
tional cognitive disorders consist of a range of overlap-
ping conditions in which cognitive symptoms, usually of
attentional nature, present characteristic internal incon-
sistency as the result of reversible changes in brain func-
tion rather than damage or disease [19]. Functional
cognitive disorders may present as an isolated syndrome,
or in the context of anxiety or depression, or alongside
other functional or somatoform symptoms such as
chronic pain [19]. Some individuals with functional cog-
nitive disorders may perform in the mildly impaired
range on cognitive tests [19]. Where a positive diagnosis
of functional cognitive disorders is made, appropriate
treatment should include a clear explanation of the diag-
nosis using supportive written material (for example,
“Functional Neurological Disorder (FND): a patient’s
guide” [22]). Worried wells do not have any specific cogni-
tive complaint, but they claim concern of declining cogni-
tion in the future, and strive to preserve it as long as
possible or even enhance it. Worried wells frequently re-
port a family history of dementia or Alzheimer’s disease.
Clearly, the target population of BHSs is remarkably
different from that of current memory clinics. The above
case-mix suggests not to refer to them as “patients,” but
to rather prefer a more neutral term such as “users.”
It is worth noting that the definition and identification
of the ideal target population might not always be clear-
cut, especially when it comes to individuals with border-
line or inconclusive cognitive testing or very mild cogni-
tive or executive dysfunctions who might still benefit of
the BHS offers. Moreover, while we expect that a larger
share of users might be classified as SCD, functional
cognitive disorders or worried wells, other groups might
access BHSs. These groups might include individuals
with mild forms of mood, anxiety, sleep, attention-
deficit/hyperactivity, or other disorders. Some of these
individuals might be eligible to enter a BHS journey
depending on BHS personnel and facilities (e.g., a psych-
iatrist or psychotherapist with experience in mood disor-
ders), while others should be referred to external
specialists. Individuals with severe psychiatric or physical
comorbidity (e.g., cardiovascular/cerebrovascular dis-
eases) will not represent the target population of BHSs.
In the perspective of growing demand and growing
offer, in the early years of BHSs, users will be referred by
memory clinics. At a later stage, as BHSs catch up, they
will consolidate their own user flow consisting of people
who spontaneously show up directly to BHSs. The im-
plementation of educational programs (e.g., awareness
campaigns on brain health for the general population)
and other initiatives [23] might increase the BHSs visi-
bility and reputation.
Missions
The four main missions of BHS are as follows: (i)
dementia risk profiling, (ii) dementia risk communica-
tion, (iii) dementia risk reduction (primary and
secondary prevention), and (iv) cognitive enhancement.
These topics are exhaustively discussed in the
pertinent papers [24–27], and briefly summarized
below.
Education of the general public and health care pro-
viders might be a mission of BHSs in academic settings.
This will not be addressed in this paper as it will be of
interest to a minority of academic BHSs and is beyond
the scope of this initiative.
Dementia risk profiling
The very first step of assessment in BHSs will be un-
derstanding the user’s request. Anecdotal observations
indicate that a number of individuals with SCD, func-
tional cognitive disorders, or worried wells look for
reassurance. Indeed, malaises such as psychological/
psychiatric (e.g., depression, trauma, affective issues)
or personal issues (e.g., divorce, violent spouse, un-
employment, societal issues) are sometimes presented
in disguise as “memory” concerns. A careful history
collection, carried out with tact and empathy, can be
revealing. In such cases, a “blind” offer of dementia
risk assessment would be a clinical misstep. The BHS
clinician should here refer the user to the appropriate
specialist.
The following step to the implementation of personal-
ized prevention plans is to identify users’ risk factors for
dementia. The relative risk of modifiable dementia risk
factors varies widely between 1.1 for air pollution to 1.9
for hearing loss and depression [15] and dramatically in-
creases for genetic (APOE ɛ4 genotype) and biological
(amyloid and tau deposition) risk factors [16]. BHSs
must be able to comprehensively assess, combine (e.g.,
through composite dementia risk scores such as the
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Cardiovascular Risk Factors, Aging, and Incidence of De-
mentia (CAIDE) Dementia Risk Score [28]; the Brief De-
mentia Screening Indicator [29]; and the Australian
National University Alzheimer’s Disease Risk Index [30,
31]), and interpret all these risk factors together with
protective factors, and to finally profile and categorize
the user’s specific risk into strata (e.g., high, moderate,
or low risk of developing dementia in the following 5,
10, or 15 years). A basic level of assessment should in-
clude sociodemographic, lifestyle, and health risk factors,
followed by APOE status and biomarkers if resources
allow. Importantly, risk profiling should take into ac-
count other demographic variables such as age, gender,
and ethnicity which might influence the interpretation
of risk factors (e.g., APOE ɛ4 is associated with a higher
risk of AD in individuals aged 65–70 years [32], in
women as compared to men [33, 34], and in Japanese
and Caucasian individuals as compared to African
Americans and Hispanics [35]).
Further research is still needed to estimate the relative
risk of each risk factor adjusted for communality with
other factors; develop composite risk scores combining
modifiable, biological (e.g., amyloid and tau), and genetic
(e.g., APOE) risk factors; and develop cost-effective
screening protocols [24].
Dementia risk communication
We recommend disclosing the risk of dementia, whether
based only on lifestyles or also on genetic or biomarker
status, to users, providing expert counseling if necessary.
However, this decision should be taken on an individual
basis and taking into account user’s cultural, societal,
and economic backgrounds, belief system, and
expectations.
The communication of the concept of risk to the
general public is challenging, especially in the context
of untreatable and stigmatized neurodegenerative dis-
eases leading to dementia. Evidence on how to com-
municate dementia risk is scarce. Nevertheless, the
available literature allows to put in place some prac-
tical recommendation [25]. These recommendations
are inspired from other fields with more experience
on this topic (e.g., oncology [36–38]) and from exist-
ing research disclosure protocols of genetic (e.g.,
APOE genotype [39–42]) and biomarker (e.g.,
amyloid-PET [43–47]) results that proved to have a
well-tolerated psychological impact in the short term.
Nevertheless, we acknowledge that these disclosure
protocols are limited to explaining that genes or bio-
markers are risk factors for dementia, but do not ac-
tually communicate the risk of developing dementia
in the next few years.
We underline that the use of standardized communi-
cation protocols on an individual level is challenging and
might require a certain degree of adaptation and clinical
sensitivity. Further research is needed to develop com-
munication protocols delivering quantitative information
about individual risk, and scalable tools suitable to users
with different socio-demographic and cultural features
(including educational background). BHSs will represent
the ideal context for this research.
Finally, BHSs will need to deal with the ethics regula-
tions and potential regulatory hurdles associated with
the communication of risk (mainly so if based on genet-
ics) to the users, their families, and other actors (e.g.,
healthcare insurances, employers). Informed consent
should be given before entering a BHS journey, and con-
fidentiality should be enforced at all levels of the BHS
journey.
Dementia risk reduction
Risk reduction interventions aim to reduce the likeli-
hood of long-term cognitive decline or dementia onset
in at-risk individuals. Among all the randomized trials
on multi-domain interventions, only the FINGER study
met its primary outcome, showing greater cognitive im-
provement in participants of the experimental group
versus controls [48]. On the contrary, other randomized
trials on multi-domain interventions such as MAPT
[49], preDIVA [50], Look AHEAD [51], and DO-HEAL
TH [52] failed to meet their primary outcomes.
Interestingly, subsample analyses of the FINGER
and MAPT studies showed that interventions were
more effective in patients at increased risk for demen-
tia based on genetic (APOE ɛ4) [53] or biological
(amyloid positivity) [49] risk factors. This suggests
that personalized multi-domain interventions, tailored
to the individual’s specific risk factors (reflecting the
risk reduction potential), are likely associated to the
highest clinical benefit.
Even though preliminary evidence is now available and
allows to provide recommendations for practical imple-
mentation of precision dementia risk reduction interven-
tions [26], long-term multi-domain randomized
controlled trials are needed to provide definitive evi-
dence on their efficacy. The World Wide-FINGERS, the
first network for multimodal dementia prevention trials,
aims to fill this evidence gap by adapting and optimizing
the FINGER operational model for dementia risk reduc-
tion in different populations, and geographic and eco-
nomic settings [54].
Translation of experimental risk reduction interven-
tions to the clinical setting will not be straightforward.
Possible interventions that can be offered to BHS users
today or in the next few years might cover one of more
of the following areas: diet, exercise, cognitive training,
and vascular risk monitoring (inspired by current cardio-
vascular prevention programs) [26].
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Finally, we underline the importance of correcting sen-
sory impairment or emotional disorders (e.g., anxiety or
depression) as a prerequisite for the implementation of
effective dementia risk reduction intervention.
Cognitive enhancement
Cognitive enhancement interventions aim to improve
the individual’s performance and abilities. These inter-
ventions are typically performed over a time span of a
few days/weeks. Cognitive enhancement interventions
include cognitive, mental, and physical training (includ-
ing mindfulness); non-invasive brain stimulation; and
cognitive-enhancement drugs. To date, currently avail-
able evidence supporting the efficacy of cognitive train-
ing is limited and heterogeneous but generally positive,
while that supporting the efficacy of mindfulness and
tDCS interventions might possibly increase in the next
few years. Evidence on cognitive-enhancing drugs is
poor and inconclusive [27].
Personnel and expertise
The dementia domain is largely interdisciplinary and
spans neurology, geriatrics, psychiatry, cognitive psych-
ology, neuropsychology, nursing, and social sciences. In-
deed, BHSs should be led by multidisciplinary teams to
cover all these areas. Expertise in psychology and/or
neuropsychology is necessary for the initial (and poten-
tial follow-up) clinical and cognitive evaluations, to com-
municate the risk, and to implement cognitive
interventions. Medical expertise (e.g., in neurology, geri-
atrics, psychiatry) is necessary to define indications for
entering the BHS track, carry out exams, interpret bio-
logical and genetic risk factors, prioritize risk, set risk re-
duction interventions, and propose follow-up if needed.
Nursing competences might be necessary to collect sam-
ples and measures for risk factor assessment (e.g., bio-
logical samples, blood pressure). Further expertise, such
as nutrition or a physical training, might be useful to
cover some specific areas of prevention.
BHSs will wish to recruit personnel based on the re-
quired expertise rather than on a priori defined profes-
sional categories. For example, although current job
descriptions usually suggest that dementia risk commu-
nication should be done by a physician, we believe that a
psychologist with appropriate training, empathy, and
communication skills can safely perform this task. Post-
graduate courses on the care of persons with cognitive
disorders that are active or being launched in Europe
will help educate BHS professionals [55].
Basic vs advanced BHSs
Not all BHSs will need to cover the whole range of po-
tential health offer. We envision at least two levels, basic
and advanced, depending on resources and available
facilities. Basic services may consist of (i) standardized
risk assessment based on lifestyles, vascular and basic
genetic risk factors (e.g., APOE), and possibly measures
reflecting structural brain health (e.g., qualitative or
quantitative measures of atrophy and vascular changes),
implementing low-level composite dementia risk scores
(e.g., the CAIDE Dementia Risk Score); (ii) adaptation
and use of current practices for dementia risk communi-
cation; (iii) implementation of standardized non-
pharmacological primary prevention protocols (e.g.,
FINGER and MAPT interventions) and pharmacological
and non-pharmacological control of cardiovascular risk
factors; and (iv) cognitive enhancement using cognitive
training.
An advanced version of BHSs may expand the basic
services with one or more of the following: (i)
molecular imaging biomarkers (e.g., amyloid-PET, tau-
PET, MRI with automated image post-processing)
and/or CSF biomarkers (e.g., Aβ42, phosphorylated
tau, neurofilament light), (ii) use of structured person-
alized dementia risk communication protocols taking
into account user’s specific features (e.g., educational
background), (iii) implementation of personalized
primary and secondary prevention protocols tailored
to the user’s molecular risk profile including bio-
marker derived information, and (iv) combination of
sophisticated and personalized cognitive enhancement
techniques (e.g., cognitive training and non-invasive
brain stimulation).
As of today, some of basic BHSs’ activities (e.g.,
primary prevention) could be absorbed by general
practice depending on the structure of local health-
care provision and local opportunities. On the
contrary, at the current state of science and technol-
ogy, most of the advanced BHSs’ activities (e.g.,
secondary prevention) cannot take place in the general
practice. The availability of blood-based biomarkers
may change the scenario only if shown to be suffi-
ciently specific and in the presence of a well-tolerated
preventive drug.
Facilities
The main technological facilities needed in BHSs are
largely the same of a traditional memory clinic and
might include MRI, PET, and fully automated CSF ana-
lysis platforms (e.g., Elecsys, Lumipulse).
Other facilities will be specific to BHSs and may in-
clude tablets for computerized cognitive training, phys-
ical activity monitors, and fitness trackers.
As is the case of current memory clinics, local
factors such as availability of technology or expertise,
or idiosyncrasies towards a given diagnostic or inter-
vention technology will give individual BHSs their
specificity.
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Context for BHS implementation
BHSs can be either hybrid or stand-alone services. In the
first case, BHSs can leverage on the current memory
clinics’ structure and ongoing collaborations (with nu-
clear medicine, radiology, biochemistry laboratories,
etc.). BHS-specific expertise and technology will need to
be integrated, since some personnel and facilities are
often lacking in memory clinics such as psychothera-
pists, nutrition experts, physical trainers, and devices for
transcranial stimulation. The investment in this case
would be relatively modest. In the second case, stand-
alone BHSs will need new personnel and facilities and to
build collaborations with other services. The investment
in this case would obviously be significantly higher. In
either case, since stroke centers are already dealing with
the implementation of cardiovascular prevention pro-
grams and the promotion of awareness-rising campaigns
(both key aspects of BHSs), BHSs can partner with them
and leverage on their longstanding expertise.
Whatever the setup, a tight collaboration between
BHSs and memory clinics is strongly encouraged by this
working group. Indeed, memory clinics can refer cogni-
tively unimpaired patients to BHSs in order to investi-
gate their request and provide meaningful answers.
Conversely, BHSs can refer cognitively impaired users to
memory clinics in order to start proper diagnostic
workup and treatment.
Similar initiatives
The BHS initiative has some similarities with previous
initiatives. For example, a similar approach has been pre-
viously adopted by two Alzheimer’s Prevention Clinics
whose mission is to provide personalized therapeutic in-
terventions, based on the individual risk profile, in pa-
tients at risk for AD [56]. This approach was clearly
presented in a paper describing in detail the supporting
methodology as well as the proposed risk reduction in-
terventions and the associated challenges [56]. Briefly,
patients entering the Alzheimer’s Prevention Clinics
undergo a basic assessment of genetic, lifestyle, and car-
diovascular risk factors followed by personalized thera-
peutic interventions. We acknowledge that the basic
BHSs (as described in the “Basic vs advanced BHSs” sec-
tion) might resemble, at least in some aspects, the Alz-
heimer’s Prevention Clinics. Nevertheless, the advanced
BHSs will allow to take a step forward towards a more
comprehensive and accurate risk profiling by assessing
molecular biomarkers, and more effective risk reduction
interventions tailored to the user’s molecular risk profile.
In the last few years, several “trial-ready” cohort pro-
jects have been launched, the most relevant of which are
EPAD [57] and TRC-PAD [58]. Such projects aim to re-
cruit and screen participants in order to assemble deeply
phenotyped cohorts which provide a pool of participants
to clinical trials. Indeed, the only offer of “trial-ready”
projects is inclusion in clinical trial, and their target
population most of the times consists only of amyloid-
positive individuals. Differently, BHSs will deliver mul-
tiple pharmaceutical and non-pharmaceutical risk reduc-
tion interventions and their target population in broader
covering older or middle-aged adults with variable risk
profiles. These differences make the BHS initiative
unique of its kind.
BHS challenges
Equity and societal challenges
One of the main challenges will consist in making BHSs
equitable, i.e., accessible to the general population re-
gardless of their economic status. Most interventions po-
tentially offered by BHSs are not reimbursed in any
Western country; they may take place in for-profit enter-
prises where users pay interventions with out-of-pocket
money. Indeed, BHSs, at least at their first development
stages, will thrive mainly in higher-income countries for
the greater social awareness of cognitive diseases. As a
consequence, access may be limited to the more affluent
and more highly educated members of society. Paradox-
ically, the population that would benefit the most from
the BHSs is the one likely to be excluded (at least ini-
tially). Indeed, individuals with disadvantaged conditions,
lower education, and lower socioeconomic status are
likely those with higher risk of dementia and who might
benefit the most from risk reduction and cognitive en-
hancement interventions. See Milne et al. [59] for a dee-
per discussion on this topic. The affiliation to an existing
memory clinic or stroke center might facilitate the
coverage at least some procedures by healthcare
insurances.
Individual interventions vs large-scale population
interventions
The European Task Force for Brain Health Services is
largely made of clinicians and clinical researchers who
are by mission focused on individuals rather than on so-
ciety as a whole. Indeed, even though BHSs can sporad-
ically touch the general population (e.g., by awareness
promoting campaigns on brain health), their mission is
the implementation of personalized prevention plans tai-
lored to the individual’s risk profile. This is the so-called
“high-risk approach” that has contributed to dramatically
decrease stroke morbidity and mortality over the past
decades [60].
Nevertheless, the authors acknowledge that well-
designed and implemented prevention initiatives at the
population level might be associated with great societal
benefit, if only in the long term. Such interventions re-
quire the direct engagement of healthcare systems and
payers and strong evidence supporting the efficacy of
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interventions [61]. BHSs may contribute to the produc-
tion of this evidence, while they may or may not be the
hubs of prevention initiatives at the population level.
Sustainability
Depending on the context (see the “Context for BHS im-
plementation” section), a BHSs will require variable
amount of funding to be financially sustainable. It is
likely that business models for BHSs will develop
through several stages. Initial resources may come from
grants, philanthropy, and channeling research income/
overheads into the establishment of innovator sites that
will by necessity be located in university teaching hospi-
tals. Such settings will not need to invest heavily in up-
front capital costs for, e.g., MRI scanners. These settings
must commit to generating substantial evidence on ac-
cess and health outcomes to deliver both short- and
long- term health economic analysis. These will be lo-
cally derived to take to the local health care funders and
will be nuanced to reflect the needs/motivations of the
purchaser.
The purchasing by the extant health providers has to
be the exit strategy for the reactive initial funding. One
could argue that a 5-year period of funding for “pilot or
innovator” sites is sufficient to make the argument to
transition to centralized funding by, e.g., Healthcare
Commissioners in the NHS. This will be supported by,
e.g., NICE guidance and other clinical policy documents
that will support individual practitioners in making their
business case. Reports from advocacy groups whilst
helpful are no replacement for policy documents gener-
ated in an unbiased fashion by organizations like NICE.
Finally, the patient perspectives on the service can act as a
powerful motivator for change. Collecting data on their ex-
perience will help the development of services as well as
their extension to other regions of the country in question.
Of course, investors in the market of private health-
care may also wish to seize the opportunity of investing
in this growing market. The setups of BHSs in already
existing structures (e.g., memory clinics or stroke cen-
ters) will minimize the amount of the investment.
Research
In order to promote equity and sustainability, BHSs
should integrate their offer with continuing research activ-
ity. Sound evidence produced by BHSs research activity
might contribute to (i) identifying the trajectories of the
underlying pathologies by the follow-up of individuals at a
preclinical stage, (ii) selecting individuals at high risk for
the inclusion in clinical trials aimed at studying the effi-
cacy of disease-modifying therapies at a preclinical asymp-
tomatic stage of the disease, (iii) producing strong
scientific evidence on the efficacy of interventions (or lack
thereof), (iv) making structural efforts to access more
marginalized communities by design, and (v) drawing at-
tention of healthcare systems and persuade them to pro-
vide coverage, making BHS sustainable and equitable.
Discussion
The increasing prevalence of dementia, the awareness of the
general population on brain health, recent advancements in
technology and knowledge of neurodegenerative diseases,
and preliminary evidence of effective risk reduction interven-
tions constitute the rationale behind the development of
BHSs. BHSs will focus on a new target population (cogni-
tively unimpaired individuals concerned with the preserva-
tion or improvement of their cognitive abilities); have specific
missions (dementia risk profiling, dementia risk communica-
tion, dementia risk reduction, and cognitive enhancement);
face relevant challenges (demonstrating efficacy, equity and
sustainability of the services); and require high-level expertise,
facilities, and personnel. BHSs might rely on the current
memory clinics or be independent services.
The current aim of this BHS initiative is to raise
awareness on the need for new services aimed at cur-
rently underserved group individuals and provide a large
set of recommended interventions which should be lo-
cally adapted by healthcare providers based on local
needs and resources.
The future of BHSs
We envision that BHSs might change in the upcoming
years thanks to research advances and novel
technologies.
Dementia risk profiling
The clinical validation of blood-based biomarkers of
amyloid [62], tau [63], and neurodegeneration (e.g., neu-
rofilament light [64]) will radically change the way indi-
vidual risk is assessed. Indeed, blood-based biomarkers
are much cheaper than molecular imaging and much
more accessible. We envision a scenario where blood-
based biomarkers with high sensitivity for abnormality
will be used for large-scale dementia screening, thus re-
ducing the number of users requiring more expensive
testing. Polygenic risk scores may also make the transi-
tion to clinical fruition in the coming years. The wide-
spread use of calculators (e.g., ADappt [65]) will allow a
comprehensive interpretation of multiple risk factors
and the quantification of the user’s risk. Finally, the use
of brain health registries [66, 67] and digital tools will fa-
cilitate the access of users to BHSs.
Dementia risk communication
Large-scale education programs will result in increased
awareness of the general population on brain health. A
more educated and aware population has a better predis-
position to understand the concept of risk. Nevertheless,
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further research is needed to develop and implement
proper communication strategies on an individual level.
Dementia risk reduction
Aducanumab [68, 69] might be the very first disease-
modifying therapy approved by the FDA for clinical use
in patients with prodromal Alzheimer’s disease or mild
Alzheimer’s disease dementia. Several phase 3 clinical
trials on anti-amyloid drugs in cognitively healthy indi-
viduals are currently ongoing, and their results are ex-
pected between 2021 and 2025 [70]. If they prove to be
effective, disease-modifying therapies will be the main
weapon to prevent cognitive deterioration in cognitively
unimpaired biomarker-positive individuals. In the opti-
mistic scenario of an effective disease-modifying therapy,
BHSs will play a key role in screening the population
and delivering such therapies.
However, whether disease-modifying therapies will be
available or not, more targeted personalized multido-
main interventions will be increasingly fine-tuned and
implemented in BHSs [54].
Cognitive enhancement
In the next few years, protocols combining cognitive
training, mindfulness, and non-invasive brain stimula-
tion might be available, although the timelines are even
harder to predict than for industry-sponsored pharmaco-
logical clinical trials.
This provides an example of how BHSs might operate
when blood-based biomarkers are available. In this
Fig. 1 BHS activities today and in the next few years, in comparison with memory clinics
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scenario, users undergo screening including assessment
of APOE genotype and lifestyle risk factors as well as
high-sensitivity blood-based biomarkers. Those users
with positive or borderline blood-based biomarkers
might also undergo a second-level assessment with mo-
lecular imaging (e.g., amyloid-PET, tau-PET), even if this
might be not necessary if blood-based biomarkers prove
to be highly accurate (in terms of both high sensitivity
and specificity). Taken together, this information allows
to profile the user’s risk and classify it (e.g., as “low,”
“moderate,” or “high” based on a composite relative
risk). Afterward, the risk is communicated to the user.
Finally, the intervention is chosen accordingly: users
with low risk might start personalized cognitive en-
hancement interventions, while users with moderate or
high risk should undergo personalized risk reduction in-
terventions possibly including disease-modifying therap-
ies. This is a purely indicative scenario and can vary
based on the context of BHS implementation. CT, com-
puterized tomography; MRI, magnetic resonance im-
aging; FDG, fluorodeoxyglucose; PET, positron emission
tomography; APOE, apolipoprotein E; RR, relative risk;
BBB, blood-based biomarkers; DMT, disease-modifying
therapies. The risk operationalization of “low” (RR = 1–
2), “moderate” (RR = 2–4), and “high” (RR > 4) intended
to be indicative and is used for illustrative purposes
only.
Figure 1 provides an example of how BHSs might
operate.
Conclusion
Despite the many organizational and structural chal-
lenges to be faced, we envision that the development of
BHSs will play a key role in the fight against the increas-
ing dementia prevalence by embracing the needs of cog-
nitively unimpaired individuals who wish to preserve or
improve their cognitive abilities.
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